世界の腎芽腫治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Nephroblastoma Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4054 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、腎芽腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ダクチノマイシン、ドキソルビシン、ビンクリスチン、シクロホスファミド、エトポシド、イリノテカン）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・腎芽腫治療の市場動向 ・企業の競争状況、市場シェア ・腎芽腫治療の種類別市場規模（ダクチノマイシン、ドキソルビシン、ビンクリスチン、シクロホスファミド、エトポシド、イリノテカン） ・腎芽腫治療の用途別市場規模（病院、専門クリニック、その他） ・腎芽腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・腎芽腫治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・腎芽腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腎芽腫治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・腎芽腫治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bayer HealthCare、Roche、Pfizer、Sanofi Pasteur、Merck、MediLexicon、Bristol-Myers Squibb Company、Apotex） ・結論

Nephroblastoma is a cancer of the kidneys that typically occurs in children, rarely in adults. Approximately 500 cases are diagnosed in the U.S. annually. The majority (75%) occurs in otherwise normal children; a minority (25%) is associated with other developmental abnormalities. It is highly responsive to treatment, with about 90% of patients surviving at least five years.
The overall 5-year survival is estimated to be approximately 90%, but for individuals the prognosis is highly dependent on individual staging and treatment. Early removal tends to promote positive outcomes.

Market Analysis and Insights: Global Nephroblastoma Treatment Market
The global Nephroblastoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nephroblastoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nephroblastoma Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nephroblastoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nephroblastoma Treatment market.

Global Nephroblastoma Treatment Scope and Market Size
Nephroblastoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nephroblastoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Drug and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Drug
Dactinomycin
Doxorubicin
Vincristine
Cyclophosphamide
Etoposide
Irinotecan

Segment by Application
Hospitals
Specialty Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer HealthCare
Roche
Pfizer
Sanofi Pasteur
Merck
MediLexicon
Bristol-Myers Squibb Company
Apotex

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nephroblastoma Treatment Market Size Growth Rate by Drug: 2016 VS 2021 VS 2027
1.2.2 Dactinomycin
1.2.3 Doxorubicin
1.2.4 Vincristine
1.2.5 Cyclophosphamide
1.2.6 Etoposide
1.2.7 Irinotecan
1.3 Market by Application
1.3.1 Global Nephroblastoma Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Nephroblastoma Treatment Market Perspective (2016-2027)
2.2 Nephroblastoma Treatment Growth Trends by Regions
2.2.1 Nephroblastoma Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Nephroblastoma Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Nephroblastoma Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Nephroblastoma Treatment Industry Dynamic
2.3.1 Nephroblastoma Treatment Market Trends
2.3.2 Nephroblastoma Treatment Market Drivers
2.3.3 Nephroblastoma Treatment Market Challenges
2.3.4 Nephroblastoma Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Nephroblastoma Treatment Players by Revenue
3.1.1 Global Top Nephroblastoma Treatment Players by Revenue (2016-2021)
3.1.2 Global Nephroblastoma Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Nephroblastoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Nephroblastoma Treatment Revenue
3.4 Global Nephroblastoma Treatment Market Concentration Ratio
3.4.1 Global Nephroblastoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nephroblastoma Treatment Revenue in 2020
3.5 Nephroblastoma Treatment Key Players Head office and Area Served
3.6 Key Players Nephroblastoma Treatment Product Solution and Service
3.7 Date of Enter into Nephroblastoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Nephroblastoma Treatment Breakdown Data by Drug
4.1 Global Nephroblastoma Treatment Historic Market Size by Drug (2016-2021)
4.2 Global Nephroblastoma Treatment Forecasted Market Size by Drug (2022-2027)

5 Nephroblastoma Treatment Breakdown Data by Application
5.1 Global Nephroblastoma Treatment Historic Market Size by Application (2016-2021)
5.2 Global Nephroblastoma Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Nephroblastoma Treatment Market Size (2016-2027)
6.2 North America Nephroblastoma Treatment Market Size by Drug
6.2.1 North America Nephroblastoma Treatment Market Size by Drug (2016-2021)
6.2.2 North America Nephroblastoma Treatment Market Size by Drug (2022-2027)
6.2.3 North America Nephroblastoma Treatment Market Size by Drug (2016-2027)
6.3 North America Nephroblastoma Treatment Market Size by Application
6.3.1 North America Nephroblastoma Treatment Market Size by Application (2016-2021)
6.3.2 North America Nephroblastoma Treatment Market Size by Application (2022-2027)
6.3.3 North America Nephroblastoma Treatment Market Size by Application (2016-2027)
6.4 North America Nephroblastoma Treatment Market Size by Country
6.4.1 North America Nephroblastoma Treatment Market Size by Country (2016-2021)
6.4.2 North America Nephroblastoma Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Nephroblastoma Treatment Market Size (2016-2027)
7.2 Europe Nephroblastoma Treatment Market Size by Drug
7.2.1 Europe Nephroblastoma Treatment Market Size by Drug (2016-2021)
7.2.2 Europe Nephroblastoma Treatment Market Size by Drug (2022-2027)
7.2.3 Europe Nephroblastoma Treatment Market Size by Drug (2016-2027)
7.3 Europe Nephroblastoma Treatment Market Size by Application
7.3.1 Europe Nephroblastoma Treatment Market Size by Application (2016-2021)
7.3.2 Europe Nephroblastoma Treatment Market Size by Application (2022-2027)
7.3.3 Europe Nephroblastoma Treatment Market Size by Application (2016-2027)
7.4 Europe Nephroblastoma Treatment Market Size by Country
7.4.1 Europe Nephroblastoma Treatment Market Size by Country (2016-2021)
7.4.2 Europe Nephroblastoma Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Nephroblastoma Treatment Market Size (2016-2027)
8.2 Asia-Pacific Nephroblastoma Treatment Market Size by Drug
8.2.1 Asia-Pacific Nephroblastoma Treatment Market Size by Drug (2016-2021)
8.2.2 Asia-Pacific Nephroblastoma Treatment Market Size by Drug (2022-2027)
8.2.3 Asia-Pacific Nephroblastoma Treatment Market Size by Drug (2016-2027)
8.3 Asia-Pacific Nephroblastoma Treatment Market Size by Application
8.3.1 Asia-Pacific Nephroblastoma Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Nephroblastoma Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Nephroblastoma Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Nephroblastoma Treatment Market Size by Region
8.4.1 Asia-Pacific Nephroblastoma Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Nephroblastoma Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Nephroblastoma Treatment Market Size (2016-2027)
9.2 Latin America Nephroblastoma Treatment Market Size by Drug
9.2.1 Latin America Nephroblastoma Treatment Market Size by Drug (2016-2021)
9.2.2 Latin America Nephroblastoma Treatment Market Size by Drug (2022-2027)
9.2.3 Latin America Nephroblastoma Treatment Market Size by Drug (2016-2027)
9.3 Latin America Nephroblastoma Treatment Market Size by Application
9.3.1 Latin America Nephroblastoma Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Nephroblastoma Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Nephroblastoma Treatment Market Size by Application (2016-2027)
9.4 Latin America Nephroblastoma Treatment Market Size by Country
9.4.1 Latin America Nephroblastoma Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Nephroblastoma Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Nephroblastoma Treatment Market Size (2016-2027)
10.2 Middle East & Africa Nephroblastoma Treatment Market Size by Drug
10.2.1 Middle East & Africa Nephroblastoma Treatment Market Size by Drug (2016-2021)
10.2.2 Middle East & Africa Nephroblastoma Treatment Market Size by Drug (2022-2027)
10.2.3 Middle East & Africa Nephroblastoma Treatment Market Size by Drug (2016-2027)
10.3 Middle East & Africa Nephroblastoma Treatment Market Size by Application
10.3.1 Middle East & Africa Nephroblastoma Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Nephroblastoma Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Nephroblastoma Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Nephroblastoma Treatment Market Size by Country
10.4.1 Middle East & Africa Nephroblastoma Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Nephroblastoma Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer HealthCare
11.1.1 Bayer HealthCare Company Details
11.1.2 Bayer HealthCare Business Overview
11.1.3 Bayer HealthCare Nephroblastoma Treatment Introduction
11.1.4 Bayer HealthCare Revenue in Nephroblastoma Treatment Business (2016-2021)
11.1.5 Bayer HealthCare Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Nephroblastoma Treatment Introduction
11.2.4 Roche Revenue in Nephroblastoma Treatment Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Nephroblastoma Treatment Introduction
11.3.4 Pfizer Revenue in Nephroblastoma Treatment Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Sanofi Pasteur
11.4.1 Sanofi Pasteur Company Details
11.4.2 Sanofi Pasteur Business Overview
11.4.3 Sanofi Pasteur Nephroblastoma Treatment Introduction
11.4.4 Sanofi Pasteur Revenue in Nephroblastoma Treatment Business (2016-2021)
11.4.5 Sanofi Pasteur Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Nephroblastoma Treatment Introduction
11.5.4 Merck Revenue in Nephroblastoma Treatment Business (2016-2021)
11.5.5 Merck Recent Development
11.6 MediLexicon
11.6.1 MediLexicon Company Details
11.6.2 MediLexicon Business Overview
11.6.3 MediLexicon Nephroblastoma Treatment Introduction
11.6.4 MediLexicon Revenue in Nephroblastoma Treatment Business (2016-2021)
11.6.5 MediLexicon Recent Development
11.7 Bristol-Myers Squibb Company
11.7.1 Bristol-Myers Squibb Company Company Details
11.7.2 Bristol-Myers Squibb Company Business Overview
11.7.3 Bristol-Myers Squibb Company Nephroblastoma Treatment Introduction
11.7.4 Bristol-Myers Squibb Company Revenue in Nephroblastoma Treatment Business (2016-2021)
11.7.5 Bristol-Myers Squibb Company Recent Development
11.8 Apotex
11.8.1 Apotex Company Details
11.8.2 Apotex Business Overview
11.8.3 Apotex Nephroblastoma Treatment Introduction
11.8.4 Apotex Revenue in Nephroblastoma Treatment Business (2016-2021)
11.8.5 Apotex Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Nephroblastoma Treatment Market Size Growth Rate by Drug (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Dactinomycin
Table 3. Key Players of Doxorubicin
Table 4. Key Players of Vincristine
Table 5. Key Players of Cyclophosphamide
Table 6. Key Players of Etoposide
Table 7. Key Players of Irinotecan
Table 8. Global Nephroblastoma Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Nephroblastoma Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Nephroblastoma Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Nephroblastoma Treatment Market Share by Regions (2016-2021)
Table 12. Global Nephroblastoma Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Nephroblastoma Treatment Market Share by Regions (2022-2027)
Table 14. Nephroblastoma Treatment Market Trends
Table 15. Nephroblastoma Treatment Market Drivers
Table 16. Nephroblastoma Treatment Market Challenges
Table 17. Nephroblastoma Treatment Market Restraints
Table 18. Global Nephroblastoma Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Nephroblastoma Treatment Market Share by Players (2016-2021)
Table 20. Global Top Nephroblastoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nephroblastoma Treatment as of 2020)
Table 21. Ranking of Global Top Nephroblastoma Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Nephroblastoma Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Nephroblastoma Treatment Product Solution and Service
Table 25. Date of Enter into Nephroblastoma Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 28. Global Nephroblastoma Treatment Revenue Market Share by Drug (2016-2021)
Table 29. Global Nephroblastoma Treatment Forecasted Market Size by Drug (2022-2027) (US$ Million)
Table 30. Global Nephroblastoma Treatment Revenue Market Share by Drug (2022-2027) & (US$ Million)
Table 31. Global Nephroblastoma Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Nephroblastoma Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Nephroblastoma Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Nephroblastoma Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 36. North America Nephroblastoma Treatment Market Size by Drug (2022-2027) & (US$ Million)
Table 37. North America Nephroblastoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Nephroblastoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Nephroblastoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Nephroblastoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 42. Europe Nephroblastoma Treatment Market Size by Drug (2022-2027) & (US$ Million)
Table 43. Europe Nephroblastoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Nephroblastoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Nephroblastoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Nephroblastoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 48. Asia-Pacific Nephroblastoma Treatment Market Size by Drug (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Nephroblastoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Nephroblastoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Nephroblastoma Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Nephroblastoma Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 54. Latin America Nephroblastoma Treatment Market Size by Drug (2022-2027) & (US$ Million)
Table 55. Latin America Nephroblastoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Nephroblastoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Nephroblastoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Nephroblastoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Nephroblastoma Treatment Market Size by Drug (2016-2021) (US$ Million)
Table 60. Middle East & Africa Nephroblastoma Treatment Market Size by Drug (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Nephroblastoma Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Nephroblastoma Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Nephroblastoma Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Nephroblastoma Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Bayer HealthCare Company Details
Table 66. Bayer HealthCare Business Overview
Table 67. Bayer HealthCare Nephroblastoma Treatment Product
Table 68. Bayer HealthCare Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 69. Bayer HealthCare Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Nephroblastoma Treatment Product
Table 73. Roche Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Nephroblastoma Treatment Product
Table 78. Pfizer Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 79. Pfizer Recent Development
Table 80. Sanofi Pasteur Company Details
Table 81. Sanofi Pasteur Business Overview
Table 82. Sanofi Pasteur Nephroblastoma Treatment Product
Table 83. Sanofi Pasteur Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 84. Sanofi Pasteur Recent Development
Table 85. Merck Company Details
Table 86. Merck Business Overview
Table 87. Merck Nephroblastoma Treatment Product
Table 88. Merck Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 89. Merck Recent Development
Table 90. MediLexicon Company Details
Table 91. MediLexicon Business Overview
Table 92. MediLexicon Nephroblastoma Treatment Product
Table 93. MediLexicon Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 94. MediLexicon Recent Development
Table 95. Bristol-Myers Squibb Company Company Details
Table 96. Bristol-Myers Squibb Company Business Overview
Table 97. Bristol-Myers Squibb Company Nephroblastoma Treatment Product
Table 98. Bristol-Myers Squibb Company Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 99. Bristol-Myers Squibb Company Recent Development
Table 100. Apotex Company Details
Table 101. Apotex Business Overview
Table 102. Apotex Revenue in Nephroblastoma Treatment Business (2016-2021) & (US$ Million)
Table 103. Apotex Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nephroblastoma Treatment Market Share by Drug: 2020 VS 2027
Figure 2. Dactinomycin Features
Figure 3. Doxorubicin Features
Figure 4. Vincristine Features
Figure 5. Cyclophosphamide Features
Figure 6. Etoposide Features
Figure 7. Irinotecan Features
Figure 8. Global Nephroblastoma Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Specialty Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Nephroblastoma Treatment Report Years Considered
Figure 13. Global Nephroblastoma Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Nephroblastoma Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Nephroblastoma Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Nephroblastoma Treatment Market Share by Regions (2022-2027)
Figure 17. Global Nephroblastoma Treatment Market Share by Players in 2020
Figure 18. Global Top Nephroblastoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nephroblastoma Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Nephroblastoma Treatment Revenue in 2020
Figure 20. Global Nephroblastoma Treatment Revenue Market Share by Drug (2016-2021)
Figure 21. Global Nephroblastoma Treatment Revenue Market Share by Drug (2022-2027)
Figure 22. North America Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Nephroblastoma Treatment Market Share by Drug (2016-2027)
Figure 24. North America Nephroblastoma Treatment Market Share by Application (2016-2027)
Figure 25. North America Nephroblastoma Treatment Market Share by Country (2016-2027)
Figure 26. United States Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Nephroblastoma Treatment Market Share by Drug (2016-2027)
Figure 30. Europe Nephroblastoma Treatment Market Share by Application (2016-2027)
Figure 31. Europe Nephroblastoma Treatment Market Share by Country (2016-2027)
Figure 32. Germany Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Nephroblastoma Treatment Market Share by Drug (2016-2027)
Figure 40. Asia-Pacific Nephroblastoma Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Nephroblastoma Treatment Market Share by Region (2016-2027)
Figure 42. China Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Nephroblastoma Treatment Market Share by Drug (2016-2027)
Figure 50. Latin America Nephroblastoma Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Nephroblastoma Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Nephroblastoma Treatment Market Share by Drug (2016-2027)
Figure 56. Middle East & Africa Nephroblastoma Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Nephroblastoma Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Nephroblastoma Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Bayer HealthCare Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 64. Sanofi Pasteur Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 66. MediLexicon Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 67. Bristol-Myers Squibb Company Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 68. Apotex Revenue Growth Rate in Nephroblastoma Treatment Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---